A 2-part webinar for scientists interested in novel drug delivery methods for basic research, drug discovery and development. Learn about novel infusion technologies and how challenges in physiological monitoring and drug delivery are being overcome by implantable and programmable devices.
Christian Schnell, Lab Head of in-vivo Pharmacology and Oncology Research at Novartis in Basel, Switzerland presents data from multiple species that show how differences in blood pressure, heart rate and acute stress impact drug activity and how dosing a pre-trained animal can influence hemodynamic parameters.
Additional References:
Discovering and Developing Molecules with Optimal Drug-Like Properties Editors: Allen C Templeton, Stephen R. Byrn, Roy J Haskell, Thomas E. PrisinzanoISBN: 978-1-4939-1398-5 (Print) 978-1-4939-1399-2 (Online) 27 Sep 2014  Discovery Formulations: Approaches and Practices in Early Preclinical DevelopmentShobha N. Bhattachar, David M. Bender, Stephanie A. Sweetana, James A. WesleyDiscovering and Developing Molecules with Optimal Drug-Like PropertiesAAPS Advances in the Pharmaceutical Sciences Series Volume 15, 2015, pp 49-94 Chapter 2, 27 Sep 2014Enabling Discovery Through Leveraging and Miniaturizing Pharmaceutical Principles and ProcessesRoy J. Haskell, Kimberly A. Foster, Ching Kim Tye, Michael MorgenDiscovering and Developing Molecules with Optimal Drug-Like PropertiesAAPS Advances in the Pharmaceutical Sciences Series Volume 15, 2015, pp 95-140 Chapter 3, 27 Sep 2014Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical ResearchTove Tuntland, Brian Ethell, Takatoshi Kosaka, Francesca Blasco, Richard Xu Zang, Monish Jain, Ty Gould, Keith Hoffmaster.Front. Pharmacol., 28 July 2014
Optimising in vivo pharmacology studies—Practical PKPD considerationsJohan Gabrielsson, A. Richard Green, Piet H. Van der GraafJournal of Pharmagological and Toxicological Methods, Volume 61, Issue 2, March-April 2010, pp 146-156.
Syracuse University Magazine Article on Dr Robert Doyle's Research
Presenters
Christian Schnell
Christian joined NOVARTIS (previously CIBA-GEIGY) in 1980, first in Cardiovascular Research followed by Oncology Research since 1994. He was actively involved in the profiling of several compounds that entered the clinical development and reached the market like DIOVAN®, RASILEZ®, GLEEVEC®, ZOMETA®, AFFINITOR® and PIQRAY ®. Christian was one of the first to adapt fully implantable telemetry devices for blood pressure and ECG recordings in conscious unrestrained marmosets (1993), for intraocular pressure measurements in the vitreous of conscious unrestrained rabbits (1996), and for the measurement of tumour interstitial pressure in conscious unrestrained rats and mice (2003). Currently, he is the 3R’s representative for Oncology Basel at Novartis.
Sponsor
